0.018677 0.000000 0.000000 0.000000 0.013923 0.000000 0.000000 0.000000 0.013933 0.00000 0.00000 0.00000 Jones, C.D. Andrews, D.M. Barker, A.J. Blades, K. Daunt, P. East, S. Geh, C. Graham, M.A. Johnson, K.M. Loddick, S.A. McFarland, H.M. McGregor, A. Moss, L. Rudge, D.A. Simpson, P.B. Swain, M.L. Tam, K.Y. Tucker, J.A. Walker, M. Brassington, C. Haye, H. McCall, E. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 4 90.00 90.00 90.00 53.542 71.824 71.771 C2 H4 O 44.053 ACETYL GROUP non-polymer C2 H3 O2 -1 59.044 ACETATE ION non-polymer C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C24 H30 F N7 O 451.540 N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Bioorg.Med.Chem.Lett. BMCLE8 1127 0960-894X 18 6369 10.1016/J.BMCL.2008.10.102 18996007 The Discovery of Azd5597, a Potent Imidazole Pyrimidine Amide Cdk Inhibitor Suitable for Intravenous Dosing. 2008 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 100 1 CONFOCAL MIRRORS (VARIMAX) CCD 2005-12-15 RIGAKU SATURN 92 GRAPHITE SINGLE WAVELENGTH M x-ray 1 1.54 1.0 1.54 ROTATING ANODE RIGAKU MICROMAX-007 ACETYLATION AT N-TERMINAL METHIONINE 34002.527 CELL DIVISION PROTEIN KINASE 2 2.7.11.22 1 man polymer 59.044 ACETATE ION 1 syn non-polymer 451.540 N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine 1 syn non-polymer 18.015 water 150 nat water CYCLIN DEPENDENT KINASE 2, P33 PROTEIN KINASE no yes (ACE)MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENK LYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVP VRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPD YKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL XMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLV FEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTY THEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPS FPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN sample 9606 HOMO SAPIENS Sf21 7108 SPODOPTERA FRUGIPERDA BACULOVIRUS 1 2.06 40.3 NONE 7.5 8% PEG 3350, 0.1M HEPES PH 7.5, 0.05M AMMONIUM ACETATE entity_src_gen pdbx_database_proc pdbx_database_status struct_conn repository Initial release Advisory Version format compliance Data collection Derived calculations Other Source and taxonomy 1 0 2008-11-04 1 1 2011-07-13 1 2 2019-04-24 _entity_src_gen.pdbx_host_org_cell_line _pdbx_database_status.recvd_author_approval _struct_conn.pdbx_leaving_atom_flag CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM E2F CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2- ONE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE. STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5B HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2-AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)-AMINE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({[AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- DIHYDRO-1H-INDOLE HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9-TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR HUMAN CYCLIN-DEPENDENT KINASE 2 P27(KIP1)/CYCLIN A/CDK2 COMPLEX HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4-METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN-DEPENDENT KINASE 2 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, COMPOUND 5C PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR HUMAN CYCLIN-DEPENDENT KINASE 2 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH THE INHIBITOR NU6271 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2-YLAMINE AND MONOMERIC CDK2 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN CKSHS1 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE DIN-101312 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO- INDIRUBINE CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT KINASE 2 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5- SULPHONATE BOUND IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2,4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1,4-DIAMINE THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN COMPLEX WITH THE INHIBITOR H717 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL)BENZENESULFONAMIDE HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)-AMINE CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN. CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR PDBE Y PDBE 2008-10-15 REL 1 A O HOH 2015 7.71 1 A O HOH 2016 5.94 ACT ACETATE ION I19 N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine HOH water ACT 1299 2 ACT ACT 1299 A I19 1300 3 I19 I19 1300 A HOH 2001 4 HOH HOH 2001 A HOH 2002 4 HOH HOH 2002 A HOH 2003 4 HOH HOH 2003 A HOH 2004 4 HOH HOH 2004 A HOH 2005 4 HOH HOH 2005 A HOH 2006 4 HOH HOH 2006 A HOH 2007 4 HOH HOH 2007 A HOH 2008 4 HOH HOH 2008 A HOH 2009 4 HOH HOH 2009 A HOH 2010 4 HOH HOH 2010 A HOH 2011 4 HOH HOH 2011 A HOH 2012 4 HOH HOH 2012 A HOH 2013 4 HOH HOH 2013 A HOH 2014 4 HOH HOH 2014 A HOH 2015 4 HOH HOH 2015 A HOH 2016 4 HOH HOH 2016 A HOH 2017 4 HOH HOH 2017 A HOH 2018 4 HOH HOH 2018 A HOH 2019 4 HOH HOH 2019 A HOH 2020 4 HOH HOH 2020 A HOH 2021 4 HOH HOH 2021 A HOH 2022 4 HOH HOH 2022 A HOH 2023 4 HOH HOH 2023 A HOH 2024 4 HOH HOH 2024 A HOH 2025 4 HOH HOH 2025 A HOH 2026 4 HOH HOH 2026 A HOH 2027 4 HOH HOH 2027 A HOH 2028 4 HOH HOH 2028 A HOH 2029 4 HOH HOH 2029 A HOH 2030 4 HOH HOH 2030 A HOH 2031 4 HOH HOH 2031 A HOH 2032 4 HOH HOH 2032 A HOH 2033 4 HOH HOH 2033 A HOH 2034 4 HOH HOH 2034 A HOH 2035 4 HOH HOH 2035 A HOH 2036 4 HOH HOH 2036 A HOH 2037 4 HOH HOH 2037 A HOH 2038 4 HOH HOH 2038 A HOH 2039 4 HOH HOH 2039 A HOH 2040 4 HOH HOH 2040 A HOH 2041 4 HOH HOH 2041 A HOH 2042 4 HOH HOH 2042 A HOH 2043 4 HOH HOH 2043 A HOH 2044 4 HOH HOH 2044 A HOH 2045 4 HOH HOH 2045 A HOH 2046 4 HOH HOH 2046 A HOH 2047 4 HOH HOH 2047 A HOH 2048 4 HOH HOH 2048 A HOH 2049 4 HOH HOH 2049 A HOH 2050 4 HOH HOH 2050 A HOH 2051 4 HOH HOH 2051 A HOH 2052 4 HOH HOH 2052 A HOH 2053 4 HOH HOH 2053 A HOH 2054 4 HOH HOH 2054 A HOH 2055 4 HOH HOH 2055 A HOH 2056 4 HOH HOH 2056 A HOH 2057 4 HOH HOH 2057 A HOH 2058 4 HOH HOH 2058 A HOH 2059 4 HOH HOH 2059 A HOH 2060 4 HOH HOH 2060 A HOH 2061 4 HOH HOH 2061 A HOH 2062 4 HOH HOH 2062 A HOH 2063 4 HOH HOH 2063 A HOH 2064 4 HOH HOH 2064 A HOH 2065 4 HOH HOH 2065 A HOH 2066 4 HOH HOH 2066 A HOH 2067 4 HOH HOH 2067 A HOH 2068 4 HOH HOH 2068 A HOH 2069 4 HOH HOH 2069 A HOH 2070 4 HOH HOH 2070 A HOH 2071 4 HOH HOH 2071 A HOH 2072 4 HOH HOH 2072 A HOH 2073 4 HOH HOH 2073 A HOH 2074 4 HOH HOH 2074 A HOH 2075 4 HOH HOH 2075 A HOH 2076 4 HOH HOH 2076 A HOH 2077 4 HOH HOH 2077 A HOH 2078 4 HOH HOH 2078 A HOH 2079 4 HOH HOH 2079 A HOH 2080 4 HOH HOH 2080 A HOH 2081 4 HOH HOH 2081 A HOH 2082 4 HOH HOH 2082 A HOH 2083 4 HOH HOH 2083 A HOH 2084 4 HOH HOH 2084 A HOH 2085 4 HOH HOH 2085 A HOH 2086 4 HOH HOH 2086 A HOH 2087 4 HOH HOH 2087 A HOH 2088 4 HOH HOH 2088 A HOH 2089 4 HOH HOH 2089 A HOH 2090 4 HOH HOH 2090 A HOH 2091 4 HOH HOH 2091 A HOH 2092 4 HOH HOH 2092 A HOH 2093 4 HOH HOH 2093 A HOH 2094 4 HOH HOH 2094 A HOH 2095 4 HOH HOH 2095 A HOH 2096 4 HOH HOH 2096 A HOH 2097 4 HOH HOH 2097 A HOH 2098 4 HOH HOH 2098 A HOH 2099 4 HOH HOH 2099 A HOH 2100 4 HOH HOH 2100 A HOH 2101 4 HOH HOH 2101 A HOH 2102 4 HOH HOH 2102 A HOH 2103 4 HOH HOH 2103 A HOH 2104 4 HOH HOH 2104 A HOH 2105 4 HOH HOH 2105 A HOH 2106 4 HOH HOH 2106 A HOH 2107 4 HOH HOH 2107 A HOH 2108 4 HOH HOH 2108 A HOH 2109 4 HOH HOH 2109 A HOH 2110 4 HOH HOH 2110 A HOH 2111 4 HOH HOH 2111 A HOH 2112 4 HOH HOH 2112 A HOH 2113 4 HOH HOH 2113 A HOH 2114 4 HOH HOH 2114 A HOH 2115 4 HOH HOH 2115 A HOH 2116 4 HOH HOH 2116 A HOH 2117 4 HOH HOH 2117 A HOH 2118 4 HOH HOH 2118 A HOH 2119 4 HOH HOH 2119 A HOH 2120 4 HOH HOH 2120 A HOH 2121 4 HOH HOH 2121 A HOH 2122 4 HOH HOH 2122 A HOH 2123 4 HOH HOH 2123 A HOH 2124 4 HOH HOH 2124 A HOH 2125 4 HOH HOH 2125 A HOH 2126 4 HOH HOH 2126 A HOH 2127 4 HOH HOH 2127 A HOH 2128 4 HOH HOH 2128 A HOH 2129 4 HOH HOH 2129 A HOH 2130 4 HOH HOH 2130 A HOH 2131 4 HOH HOH 2131 A HOH 2132 4 HOH HOH 2132 A HOH 2133 4 HOH HOH 2133 A HOH 2134 4 HOH HOH 2134 A HOH 2135 4 HOH HOH 2135 A HOH 2136 4 HOH HOH 2136 A HOH 2137 4 HOH HOH 2137 A HOH 2138 4 HOH HOH 2138 A HOH 2139 4 HOH HOH 2139 A HOH 2140 4 HOH HOH 2140 A HOH 2141 4 HOH HOH 2141 A HOH 2142 4 HOH HOH 2142 A HOH 2143 4 HOH HOH 2143 A HOH 2144 4 HOH HOH 2144 A HOH 2145 4 HOH HOH 2145 A HOH 2146 4 HOH HOH 2146 A HOH 2147 4 HOH HOH 2147 A HOH 2148 4 HOH HOH 2148 A HOH 2149 4 HOH HOH 2149 A HOH 2150 4 HOH HOH 2150 A ACE 0 n 1 ACE 0 A MET 1 n 2 MET 1 A GLU 2 n 3 GLU 2 A ASN 3 n 4 ASN 3 A PHE 4 n 5 PHE 4 A GLN 5 n 6 GLN 5 A LYS 6 n 7 LYS 6 A VAL 7 n 8 VAL 7 A GLU 8 n 9 GLU 8 A LYS 9 n 10 LYS 9 A ILE 10 n 11 ILE 10 A GLY 11 n 12 GLY 11 A GLU 12 n 13 GLU 12 A n 14 13 A THR 14 n 15 THR 14 A TYR 15 n 16 TYR 15 A GLY 16 n 17 GLY 16 A VAL 17 n 18 VAL 17 A VAL 18 n 19 VAL 18 A TYR 19 n 20 TYR 19 A LYS 20 n 21 LYS 20 A ALA 21 n 22 ALA 21 A ARG 22 n 23 ARG 22 A ASN 23 n 24 ASN 23 A LYS 24 n 25 LYS 24 A LEU 25 n 26 LEU 25 A THR 26 n 27 THR 26 A GLY 27 n 28 GLY 27 A GLU 28 n 29 GLU 28 A VAL 29 n 30 VAL 29 A VAL 30 n 31 VAL 30 A ALA 31 n 32 ALA 31 A LEU 32 n 33 LEU 32 A LYS 33 n 34 LYS 33 A LYS 34 n 35 LYS 34 A ILE 35 n 36 ILE 35 A ARG 36 n 37 ARG 36 A LEU 37 n 38 LEU 37 A ASP 38 n 39 ASP 38 A n 40 39 A n 41 40 A n 42 41 A n 43 42 A n 44 43 A VAL 44 n 45 VAL 44 A PRO 45 n 46 PRO 45 A SER 46 n 47 SER 46 A THR 47 n 48 THR 47 A ALA 48 n 49 ALA 48 A ILE 49 n 50 ILE 49 A ARG 50 n 51 ARG 50 A GLU 51 n 52 GLU 51 A ILE 52 n 53 ILE 52 A SER 53 n 54 SER 53 A LEU 54 n 55 LEU 54 A LEU 55 n 56 LEU 55 A LYS 56 n 57 LYS 56 A GLU 57 n 58 GLU 57 A LEU 58 n 59 LEU 58 A ASN 59 n 60 ASN 59 A HIS 60 n 61 HIS 60 A PRO 61 n 62 PRO 61 A ASN 62 n 63 ASN 62 A ILE 63 n 64 ILE 63 A VAL 64 n 65 VAL 64 A LYS 65 n 66 LYS 65 A LEU 66 n 67 LEU 66 A LEU 67 n 68 LEU 67 A ASP 68 n 69 ASP 68 A VAL 69 n 70 VAL 69 A ILE 70 n 71 ILE 70 A HIS 71 n 72 HIS 71 A THR 72 n 73 THR 72 A GLU 73 n 74 GLU 73 A n 75 74 A LYS 75 n 76 LYS 75 A LEU 76 n 77 LEU 76 A TYR 77 n 78 TYR 77 A LEU 78 n 79 LEU 78 A VAL 79 n 80 VAL 79 A PHE 80 n 81 PHE 80 A GLU 81 n 82 GLU 81 A PHE 82 n 83 PHE 82 A LEU 83 n 84 LEU 83 A HIS 84 n 85 HIS 84 A GLN 85 n 86 GLN 85 A ASP 86 n 87 ASP 86 A LEU 87 n 88 LEU 87 A LYS 88 n 89 LYS 88 A LYS 89 n 90 LYS 89 A PHE 90 n 91 PHE 90 A MET 91 n 92 MET 91 A ASP 92 n 93 ASP 92 A ALA 93 n 94 ALA 93 A SER 94 n 95 SER 94 A ALA 95 n 96 ALA 95 A LEU 96 n 97 LEU 96 A THR 97 n 98 THR 97 A GLY 98 n 99 GLY 98 A ILE 99 n 100 ILE 99 A PRO 100 n 101 PRO 100 A LEU 101 n 102 LEU 101 A PRO 102 n 103 PRO 102 A LEU 103 n 104 LEU 103 A ILE 104 n 105 ILE 104 A LYS 105 n 106 LYS 105 A SER 106 n 107 SER 106 A TYR 107 n 108 TYR 107 A LEU 108 n 109 LEU 108 A PHE 109 n 110 PHE 109 A GLN 110 n 111 GLN 110 A LEU 111 n 112 LEU 111 A LEU 112 n 113 LEU 112 A GLN 113 n 114 GLN 113 A GLY 114 n 115 GLY 114 A LEU 115 n 116 LEU 115 A ALA 116 n 117 ALA 116 A PHE 117 n 118 PHE 117 A CYS 118 n 119 CYS 118 A HIS 119 n 120 HIS 119 A SER 120 n 121 SER 120 A HIS 121 n 122 HIS 121 A ARG 122 n 123 ARG 122 A VAL 123 n 124 VAL 123 A LEU 124 n 125 LEU 124 A HIS 125 n 126 HIS 125 A ARG 126 n 127 ARG 126 A ASP 127 n 128 ASP 127 A LEU 128 n 129 LEU 128 A LYS 129 n 130 LYS 129 A PRO 130 n 131 PRO 130 A GLN 131 n 132 GLN 131 A ASN 132 n 133 ASN 132 A LEU 133 n 134 LEU 133 A LEU 134 n 135 LEU 134 A ILE 135 n 136 ILE 135 A ASN 136 n 137 ASN 136 A THR 137 n 138 THR 137 A GLU 138 n 139 GLU 138 A GLY 139 n 140 GLY 139 A ALA 140 n 141 ALA 140 A ILE 141 n 142 ILE 141 A LYS 142 n 143 LYS 142 A LEU 143 n 144 LEU 143 A ALA 144 n 145 ALA 144 A ASP 145 n 146 ASP 145 A PHE 146 n 147 PHE 146 A GLY 147 n 148 GLY 147 A LEU 148 n 149 LEU 148 A ALA 149 n 150 ALA 149 A n 151 150 A n 152 151 A n 153 152 A n 154 153 A n 155 154 A n 156 155 A n 157 156 A n 158 157 A n 159 158 A n 160 159 A n 161 160 A n 162 161 A n 163 162 A VAL 163 n 164 VAL 163 A VAL 164 n 165 VAL 164 A THR 165 n 166 THR 165 A LEU 166 n 167 LEU 166 A TRP 167 n 168 TRP 167 A TYR 168 n 169 TYR 168 A ARG 169 n 170 ARG 169 A ALA 170 n 171 ALA 170 A PRO 171 n 172 PRO 171 A GLU 172 n 173 GLU 172 A ILE 173 n 174 ILE 173 A LEU 174 n 175 LEU 174 A LEU 175 n 176 LEU 175 A GLY 176 n 177 GLY 176 A CYS 177 n 178 CYS 177 A LYS 178 n 179 LYS 178 A TYR 179 n 180 TYR 179 A TYR 180 n 181 TYR 180 A SER 181 n 182 SER 181 A THR 182 n 183 THR 182 A ALA 183 n 184 ALA 183 A VAL 184 n 185 VAL 184 A ASP 185 n 186 ASP 185 A ILE 186 n 187 ILE 186 A TRP 187 n 188 TRP 187 A SER 188 n 189 SER 188 A LEU 189 n 190 LEU 189 A GLY 190 n 191 GLY 190 A CYS 191 n 192 CYS 191 A ILE 192 n 193 ILE 192 A PHE 193 n 194 PHE 193 A ALA 194 n 195 ALA 194 A GLU 195 n 196 GLU 195 A MET 196 n 197 MET 196 A VAL 197 n 198 VAL 197 A THR 198 n 199 THR 198 A ARG 199 n 200 ARG 199 A ARG 200 n 201 ARG 200 A ALA 201 n 202 ALA 201 A LEU 202 n 203 LEU 202 A PHE 203 n 204 PHE 203 A PRO 204 n 205 PRO 204 A GLY 205 n 206 GLY 205 A ASP 206 n 207 ASP 206 A SER 207 n 208 SER 207 A GLU 208 n 209 GLU 208 A ILE 209 n 210 ILE 209 A ASP 210 n 211 ASP 210 A GLN 211 n 212 GLN 211 A LEU 212 n 213 LEU 212 A PHE 213 n 214 PHE 213 A ARG 214 n 215 ARG 214 A ILE 215 n 216 ILE 215 A PHE 216 n 217 PHE 216 A ARG 217 n 218 ARG 217 A THR 218 n 219 THR 218 A LEU 219 n 220 LEU 219 A GLY 220 n 221 GLY 220 A THR 221 n 222 THR 221 A PRO 222 n 223 PRO 222 A ASP 223 n 224 ASP 223 A GLU 224 n 225 GLU 224 A VAL 225 n 226 VAL 225 A VAL 226 n 227 VAL 226 A TRP 227 n 228 TRP 227 A PRO 228 n 229 PRO 228 A GLY 229 n 230 GLY 229 A VAL 230 n 231 VAL 230 A THR 231 n 232 THR 231 A SER 232 n 233 SER 232 A MET 233 n 234 MET 233 A PRO 234 n 235 PRO 234 A ASP 235 n 236 ASP 235 A TYR 236 n 237 TYR 236 A LYS 237 n 238 LYS 237 A PRO 238 n 239 PRO 238 A SER 239 n 240 SER 239 A PHE 240 n 241 PHE 240 A PRO 241 n 242 PRO 241 A LYS 242 n 243 LYS 242 A TRP 243 n 244 TRP 243 A ALA 244 n 245 ALA 244 A ARG 245 n 246 ARG 245 A GLN 246 n 247 GLN 246 A ASP 247 n 248 ASP 247 A PHE 248 n 249 PHE 248 A SER 249 n 250 SER 249 A LYS 250 n 251 LYS 250 A VAL 251 n 252 VAL 251 A VAL 252 n 253 VAL 252 A PRO 253 n 254 PRO 253 A PRO 254 n 255 PRO 254 A LEU 255 n 256 LEU 255 A ASP 256 n 257 ASP 256 A GLU 257 n 258 GLU 257 A ASP 258 n 259 ASP 258 A GLY 259 n 260 GLY 259 A ARG 260 n 261 ARG 260 A SER 261 n 262 SER 261 A LEU 262 n 263 LEU 262 A LEU 263 n 264 LEU 263 A SER 264 n 265 SER 264 A GLN 265 n 266 GLN 265 A MET 266 n 267 MET 266 A LEU 267 n 268 LEU 267 A HIS 268 n 269 HIS 268 A TYR 269 n 270 TYR 269 A ASP 270 n 271 ASP 270 A PRO 271 n 272 PRO 271 A ASN 272 n 273 ASN 272 A LYS 273 n 274 LYS 273 A ARG 274 n 275 ARG 274 A ILE 275 n 276 ILE 275 A SER 276 n 277 SER 276 A ALA 277 n 278 ALA 277 A LYS 278 n 279 LYS 278 A ALA 279 n 280 ALA 279 A ALA 280 n 281 ALA 280 A LEU 281 n 282 LEU 281 A ALA 282 n 283 ALA 282 A HIS 283 n 284 HIS 283 A PRO 284 n 285 PRO 284 A PHE 285 n 286 PHE 285 A PHE 286 n 287 PHE 286 A GLN 287 n 288 GLN 287 A ASP 288 n 289 ASP 288 A VAL 289 n 290 VAL 289 A THR 290 n 291 THR 290 A LYS 291 n 292 LYS 291 A PRO 292 n 293 PRO 292 A VAL 293 n 294 VAL 293 A PRO 294 n 295 PRO 294 A HIS 295 n 296 HIS 295 A LEU 296 n 297 LEU 296 A ARG 297 n 298 ARG 297 A LEU 298 n 299 LEU 298 A author_and_software_defined_assembly PQS 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N ILE 10 A N ILE 11 A O VAL 18 A O VAL 19 A N ALA 21 A N ALA 22 A O VAL 30 A O VAL 31 A N LYS 33 A N LYS 34 A O LEU 78 A O LEU 79 A O VAL 79 A O VAL 80 A N LEU 67 A N LEU 68 A N GLN 85 A N GLN 86 A O ILE 135 A O ILE 136 A N LEU 134 A N LEU 135 A O LYS 142 A O LYS 143 1 A CG MET 1 A CG MET 2 1 Y 1 A SD MET 1 A SD MET 2 1 Y 1 A CE MET 1 A CE MET 2 1 Y 1 A CG GLU 12 A CG GLU 13 1 Y 1 A CD GLU 12 A CD GLU 13 1 Y 1 A OE1 GLU 12 A OE1 GLU 13 1 Y 1 A OE2 GLU 12 A OE2 GLU 13 1 Y 1 A OG1 THR 14 A OG1 THR 15 1 Y 1 A CG2 THR 14 A CG2 THR 15 1 Y 1 A CG TYR 15 A CG TYR 16 1 Y 1 A CD1 TYR 15 A CD1 TYR 16 1 Y 1 A CD2 TYR 15 A CD2 TYR 16 1 Y 1 A CE1 TYR 15 A CE1 TYR 16 1 Y 1 A CE2 TYR 15 A CE2 TYR 16 1 Y 1 A CZ TYR 15 A CZ TYR 16 1 Y 1 A OH TYR 15 A OH TYR 16 1 Y 1 A CE LYS 34 A CE LYS 35 1 Y 1 A NZ LYS 34 A NZ LYS 35 1 Y 1 A CG ARG 36 A CG ARG 37 1 Y 1 A CD ARG 36 A CD ARG 37 1 Y 1 A NE ARG 36 A NE ARG 37 1 Y 1 A CZ ARG 36 A CZ ARG 37 1 Y 1 A NH1 ARG 36 A NH1 ARG 37 1 Y 1 A NH2 ARG 36 A NH2 ARG 37 1 Y 1 A CG ASP 38 A CG ASP 39 1 Y 1 A OD1 ASP 38 A OD1 ASP 39 1 Y 1 A OD2 ASP 38 A OD2 ASP 39 1 Y 1 A CD GLU 57 A CD GLU 58 1 Y 1 A OE1 GLU 57 A OE1 GLU 58 1 Y 1 A OE2 GLU 57 A OE2 GLU 58 1 Y 1 A CG LYS 75 A CG LYS 76 1 Y 1 A CD LYS 75 A CD LYS 76 1 Y 1 A CE LYS 75 A CE LYS 76 1 Y 1 A NZ LYS 75 A NZ LYS 76 1 Y 1 A CG1 VAL 164 A CG1 VAL 165 1 Y 1 A CG2 VAL 164 A CG2 VAL 165 1 Y 1 A GLY 13 A GLY 14 1 Y 1 A THR 39 A THR 40 1 Y 1 A GLU 40 A GLU 41 1 Y 1 A THR 41 A THR 42 1 Y 1 A GLU 42 A GLU 43 1 Y 1 A GLY 43 A GLY 44 1 Y 1 A ASN 74 A ASN 75 1 Y 1 A ARG 150 A ARG 151 1 Y 1 A ALA 151 A ALA 152 1 Y 1 A PHE 152 A PHE 153 1 Y 1 A GLY 153 A GLY 154 1 Y 1 A VAL 154 A VAL 155 1 Y 1 A PRO 155 A PRO 156 1 Y 1 A VAL 156 A VAL 157 1 Y 1 A ARG 157 A ARG 158 1 Y 1 A THR 158 A THR 159 1 Y 1 A TYR 159 A TYR 160 1 Y 1 A THR 160 A THR 161 1 Y 1 A HIS 161 A HIS 162 1 Y 1 A GLU 162 A GLU 163 1 Y 1 A A O O HOH HOH 2012 2123 2.05 1_555 2_564 1 A A OE2 ND2 GLU ASN 73 272 2.15 1_555 2_464 1 A ARG 36 -41.69 77.33 1 A LEU 37 -30.07 168.92 1 A THR 72 -165.69 106.30 1 A GLU 81 -36.97 131.33 1 A ALA 95 -68.12 1.50 1 A ARG 126 82.47 -13.15 1 A ASP 127 -151.21 51.82 1 A TYR 179 -109.36 63.00 1 A PRO 254 -108.42 48.63 1 A ASP 288 -98.84 33.85 39.933 -0.073 0.000 0.000 2.660 0.000 -2.587 0.941 0.923 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. DISORDERED REGIONS WERE OMITTED FROM THE MODEL, DISORDERED SIDE-CHAINS WERE TRUNCATED TO C-BETA. 0.3001 0.2416 0.244 2.150 42.930 779 15562 5.06 99.693 18.610 0.222 RANDOM LIKELY RESIDUAL 1 THROUGHOUT MOLECULAR REPLACEMENT 0.361 0.265 0.800 0.800 1.400 INTERNAL CDK2 STRUCTURE MODEL MAXIMUM LIKELIHOOD BABINET MODEL PLUS MASK 2.150 42.930 150 2396 37 0 2209 0.012 0.022 2310 0.004 0.020 1562 1.427 2.000 3137 0.914 3.000 3814 6.473 5.000 275 39.297 23.261 92 16.179 15.000 392 22.593 15.000 13 0.077 0.200 354 0.006 0.021 2518 0.001 0.020 453 0.214 0.200 480 0.181 0.200 1555 0.179 0.200 1120 0.088 0.200 1109 0.190 0.200 122 0.118 0.200 18 0.176 0.200 40 0.235 0.200 20 0.605 1.500 1403 1.089 2.000 2266 1.332 3.000 907 2.119 4.500 871 0.123 0.234 42.930 11 212 20 31.0 2.15 50.77 2W17 15575 3.0 0.10 1 6.00 3.33 99.7 0.39 2.15 2.23 2.10 1 3.30 99.9 refinement REFMAC 5.2.0005 data reduction CrystalClear data scaling CrystalClear phasing AMoRE CELL DIVISION PROTEIN KINASE 2 (E.C.2.7.11.22) CDK2 in complex with the imidazole pyrimidine amide, compound (S)-8b 1 N N 2 N N 3 N N 4 N N A PRO 45 A PRO 46 HELX_P A LYS 56 A LYS 57 1 1 12 A LEU 87 A LEU 88 HELX_P A SER 94 A SER 95 1 2 8 A PRO 100 A PRO 101 HELX_P A HIS 121 A HIS 122 1 3 22 A ALA 170 A ALA 171 HELX_P A LEU 175 A LEU 176 1 4 6 A THR 182 A THR 183 HELX_P A ARG 199 A ARG 200 1 5 18 A SER 207 A SER 208 HELX_P A GLY 220 A GLY 221 1 6 14 A GLY 229 A GLY 230 HELX_P A MET 233 A MET 234 5 7 5 A ASP 247 A ASP 248 HELX_P A VAL 252 A VAL 253 1 8 6 A ASP 256 A ASP 257 HELX_P A LEU 267 A LEU 268 1 9 12 A SER 276 A SER 277 HELX_P A ALA 282 A ALA 283 1 10 7 A HIS 283 A HIS 284 HELX_P A GLN 287 A GLN 288 5 11 5 covale 1.346 both A ACE 0 A C ACE 1 1_555 A MET 1 A N MET 2 1_555 TRANSFERASE KINASE, MITOSIS, CELL CYCLE, TRANSFERASE, SERINE/THREONINE-PROTEIN KINASE, ATP-BINDING, CELL DIVISION, PHOSPHOPROTEIN, PHOSPHORYLATION, NUCLEOTIDE-BINDING A THR 72 A THR 73 1 A GLU 73 A GLU 74 4.83 A PRO 253 A PRO 254 1 A PRO 254 A PRO 255 13.92 2W17 PDB 1 2W17 CDK2_HUMAN UNP 1 P24941 0 0 2W17 0 0 2W17 A 1 1 1 1 298 2W17 1 298 P24941 A 2 2 299 5 3 anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel anti-parallel A PHE 4 A PHE 5 A GLY 11 A GLY 12 A VAL 17 A VAL 18 A ASN 23 A ASN 24 A VAL 29 A VAL 30 A LYS 34 A LYS 35 A LEU 76 A LEU 77 A GLU 81 A GLU 82 A LEU 66 A LEU 67 A HIS 71 A HIS 72 A GLN 85 A GLN 86 A ASP 86 A ASP 87 A LEU 133 A LEU 134 A ILE 135 A ILE 136 A ILE 141 A ILE 142 A LEU 143 A LEU 144 BINDING SITE FOR RESIDUE ACE A 0 Software 5 BINDING SITE FOR RESIDUE ACT A1299 Software 2 BINDING SITE FOR RESIDUE I19 A1300 Software 14 A MET 1 A MET 2 5 1_555 A GLU 2 A GLU 3 5 1_555 A ASN 3 A ASN 4 5 1_555 A ILE 70 A ILE 71 5 1_555 A TYR 179 A TYR 180 5 1_555 A SER 106 A SER 107 2 1_555 A THR 290 A THR 291 2 1_555 A ILE 10 A ILE 11 14 1_555 A VAL 18 A VAL 19 14 1_555 A ALA 31 A ALA 32 14 1_555 A LYS 33 A LYS 34 14 1_555 A VAL 64 A VAL 65 14 1_555 A PHE 80 A PHE 81 14 1_555 A GLU 81 A GLU 82 14 1_555 A LEU 83 A LEU 84 14 1_555 A HIS 84 A HIS 85 14 1_555 A GLN 85 A GLN 86 14 1_555 A ASP 86 A ASP 87 14 1_555 A GLN 131 A GLN 132 14 1_555 A LEU 134 A LEU 135 14 1_555 A ASP 145 A ASP 146 14 1_555 19 P 21 21 21